| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Practice Guidelines as Topic | 48 | 2024 | 1050 | 11.100 |
Why?
|
| Physician-Patient Relations | 9 | 2023 | 626 | 3.370 |
Why?
|
| Evidence-Based Medicine | 14 | 2019 | 434 | 3.000 |
Why?
|
| Physicians | 8 | 2023 | 691 | 2.900 |
Why?
|
| Anticoagulants | 10 | 2022 | 428 | 1.860 |
Why?
|
| Humans | 125 | 2024 | 89760 | 1.800 |
Why?
|
| Mass Screening | 8 | 2022 | 642 | 1.540 |
Why?
|
| Primary Prevention | 4 | 2019 | 82 | 1.450 |
Why?
|
| Cardiology | 5 | 2021 | 115 | 1.430 |
Why?
|
| Pulmonary Embolism | 4 | 2021 | 228 | 1.420 |
Why?
|
| Coronary Disease | 3 | 2019 | 260 | 1.380 |
Why?
|
| Vena Cava Filters | 4 | 2021 | 97 | 1.370 |
Why?
|
| Students, Medical | 5 | 2023 | 421 | 1.370 |
Why?
|
| Biomedical Research | 4 | 2018 | 400 | 1.190 |
Why?
|
| Helicobacter Infections | 2 | 2018 | 37 | 1.160 |
Why?
|
| Helicobacter pylori | 2 | 2018 | 37 | 1.160 |
Why?
|
| Guidelines as Topic | 3 | 2021 | 160 | 1.130 |
Why?
|
| Venous Thromboembolism | 6 | 2022 | 159 | 1.130 |
Why?
|
| Cardiovascular Diseases | 4 | 2021 | 714 | 1.120 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2021 | 846 | 1.090 |
Why?
|
| Thrombolytic Therapy | 2 | 2020 | 232 | 1.050 |
Why?
|
| Chest Pain | 3 | 2022 | 42 | 1.040 |
Why?
|
| Societies, Medical | 7 | 2021 | 579 | 1.030 |
Why?
|
| Anti-Bacterial Agents | 6 | 2024 | 790 | 1.020 |
Why?
|
| Lyme Disease | 2 | 2022 | 9 | 1.010 |
Why?
|
| Osteoporosis | 3 | 2018 | 122 | 1.010 |
Why?
|
| Clinical Clerkship | 4 | 2015 | 118 | 0.970 |
Why?
|
| Atrial Fibrillation | 4 | 2021 | 357 | 0.970 |
Why?
|
| Myocardial Infarction | 3 | 2013 | 375 | 0.970 |
Why?
|
| Colonoscopy | 5 | 2020 | 280 | 0.970 |
Why?
|
| Attitude of Health Personnel | 2 | 2019 | 651 | 0.920 |
Why?
|
| Early Detection of Cancer | 3 | 2017 | 419 | 0.890 |
Why?
|
| Professional Practice | 2 | 2013 | 46 | 0.870 |
Why?
|
| Early Diagnosis | 2 | 2014 | 125 | 0.870 |
Why?
|
| Clostridium Infections | 3 | 2022 | 125 | 0.860 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2015 | 220 | 0.830 |
Why?
|
| Anxiety Disorders | 2 | 2022 | 152 | 0.820 |
Why?
|
| Borrelia burgdorferi | 1 | 2022 | 6 | 0.810 |
Why?
|
| Exercise Test | 2 | 2013 | 166 | 0.800 |
Why?
|
| American Heart Association | 4 | 2022 | 95 | 0.800 |
Why?
|
| Spider Bites | 1 | 2021 | 2 | 0.790 |
Why?
|
| Antithrombins | 3 | 2020 | 16 | 0.790 |
Why?
|
| Antibodies, Bacterial | 1 | 2022 | 100 | 0.770 |
Why?
|
| Physical Examination | 2 | 2019 | 149 | 0.770 |
Why?
|
| Research Design | 4 | 2019 | 601 | 0.760 |
Why?
|
| Disabled Persons | 1 | 2022 | 73 | 0.760 |
Why?
|
| Vitamin K | 2 | 2018 | 25 | 0.760 |
Why?
|
| Gastroplasty | 1 | 2021 | 25 | 0.750 |
Why?
|
| Fingers | 1 | 2021 | 69 | 0.750 |
Why?
|
| Classification | 1 | 2021 | 54 | 0.750 |
Why?
|
| Selection Bias | 1 | 2020 | 37 | 0.740 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2019 | 605 | 0.730 |
Why?
|
| School Admission Criteria | 1 | 2020 | 23 | 0.720 |
Why?
|
| Risk Assessment | 6 | 2020 | 2309 | 0.720 |
Why?
|
| Death | 1 | 2021 | 85 | 0.720 |
Why?
|
| Blood Transfusion | 2 | 2022 | 170 | 0.700 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2018 | 160 | 0.700 |
Why?
|
| Guilt | 1 | 2019 | 11 | 0.690 |
Why?
|
| Hematuria | 2 | 2021 | 50 | 0.690 |
Why?
|
| Terminology as Topic | 1 | 2021 | 221 | 0.690 |
Why?
|
| Emergency Service, Hospital | 4 | 2022 | 523 | 0.690 |
Why?
|
| Attitude to Death | 1 | 2019 | 36 | 0.680 |
Why?
|
| Factor Xa Inhibitors | 2 | 2019 | 23 | 0.680 |
Why?
|
| Physicians, Primary Care | 1 | 2021 | 105 | 0.680 |
Why?
|
| Decision Making | 2 | 2018 | 669 | 0.670 |
Why?
|
| Inpatients | 1 | 2022 | 310 | 0.650 |
Why?
|
| Memory | 1 | 2021 | 220 | 0.650 |
Why?
|
| Atrial Appendage | 1 | 2019 | 33 | 0.640 |
Why?
|
| Obesity, Morbid | 1 | 2021 | 236 | 0.620 |
Why?
|
| Psychotherapy | 1 | 2019 | 73 | 0.620 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2019 | 270 | 0.620 |
Why?
|
| Blood Coagulation Factors | 1 | 2018 | 20 | 0.620 |
Why?
|
| Dyspepsia | 1 | 2018 | 9 | 0.620 |
Why?
|
| Interprofessional Relations | 1 | 2019 | 122 | 0.610 |
Why?
|
| Patient Harm | 1 | 2018 | 7 | 0.610 |
Why?
|
| Perioperative Care | 2 | 2022 | 169 | 0.610 |
Why?
|
| Trust | 1 | 2019 | 98 | 0.600 |
Why?
|
| Diarrhea | 1 | 2019 | 182 | 0.600 |
Why?
|
| Peanut Hypersensitivity | 1 | 2018 | 15 | 0.600 |
Why?
|
| Diabetic Foot | 1 | 2017 | 14 | 0.600 |
Why?
|
| Secondary Prevention | 4 | 2021 | 158 | 0.590 |
Why?
|
| Bone Density Conservation Agents | 1 | 2018 | 46 | 0.590 |
Why?
|
| Psychomotor Agitation | 1 | 2017 | 26 | 0.590 |
Why?
|
| Diverticulitis, Colonic | 1 | 2017 | 11 | 0.590 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2017 | 25 | 0.580 |
Why?
|
| Polysomnography | 1 | 2017 | 151 | 0.570 |
Why?
|
| Low Back Pain | 1 | 2017 | 41 | 0.570 |
Why?
|
| Adult | 26 | 2022 | 26742 | 0.570 |
Why?
|
| Fractures, Bone | 2 | 2018 | 130 | 0.570 |
Why?
|
| Social Media | 1 | 2019 | 95 | 0.570 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2019 | 115 | 0.560 |
Why?
|
| Counseling | 2 | 2015 | 164 | 0.560 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 64 | 0.560 |
Why?
|
| Guideline Adherence | 2 | 2024 | 234 | 0.550 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2017 | 54 | 0.550 |
Why?
|
| Catheter Ablation | 1 | 2019 | 253 | 0.540 |
Why?
|
| Internship and Residency | 3 | 2021 | 1049 | 0.540 |
Why?
|
| Postthrombotic Syndrome | 1 | 2016 | 3 | 0.540 |
Why?
|
| Diagnostic Errors | 1 | 2017 | 160 | 0.540 |
Why?
|
| Antipsychotic Agents | 1 | 2017 | 131 | 0.540 |
Why?
|
| Glucose Metabolism Disorders | 1 | 2016 | 3 | 0.530 |
Why?
|
| United States | 14 | 2024 | 7037 | 0.530 |
Why?
|
| Elective Surgical Procedures | 1 | 2017 | 128 | 0.530 |
Why?
|
| Opiate Substitution Treatment | 1 | 2016 | 41 | 0.530 |
Why?
|
| Wearable Electronic Devices | 1 | 2016 | 26 | 0.530 |
Why?
|
| Hemorrhage | 1 | 2018 | 284 | 0.530 |
Why?
|
| Smartphone | 1 | 2016 | 39 | 0.530 |
Why?
|
| Referral and Consultation | 2 | 2021 | 343 | 0.520 |
Why?
|
| Calcineurin Inhibitors | 1 | 2016 | 53 | 0.520 |
Why?
|
| Dissent and Disputes | 1 | 2015 | 29 | 0.520 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2018 | 179 | 0.520 |
Why?
|
| Erythrocytes | 1 | 2016 | 254 | 0.520 |
Why?
|
| Psychotic Disorders | 1 | 2017 | 194 | 0.510 |
Why?
|
| Hypnotics and Sedatives | 1 | 2017 | 131 | 0.510 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2018 | 237 | 0.510 |
Why?
|
| Language | 1 | 2017 | 156 | 0.510 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 251 | 0.510 |
Why?
|
| Dermatitis, Atopic | 1 | 2016 | 55 | 0.510 |
Why?
|
| Educational Measurement | 2 | 2020 | 231 | 0.510 |
Why?
|
| Dementia | 1 | 2017 | 200 | 0.510 |
Why?
|
| Venous Thrombosis | 2 | 2021 | 253 | 0.500 |
Why?
|
| Peripheral Arterial Disease | 1 | 2016 | 96 | 0.500 |
Why?
|
| Pneumococcal Vaccines | 1 | 2015 | 28 | 0.500 |
Why?
|
| Consensus | 1 | 2017 | 360 | 0.490 |
Why?
|
| Preoperative Care | 1 | 2017 | 395 | 0.490 |
Why?
|
| Population Surveillance | 1 | 2016 | 216 | 0.490 |
Why?
|
| Hodgkin Disease | 1 | 2016 | 181 | 0.490 |
Why?
|
| Streptococcus pneumoniae | 1 | 2015 | 49 | 0.490 |
Why?
|
| Feedback, Psychological | 1 | 2015 | 19 | 0.490 |
Why?
|
| Pneumococcal Infections | 1 | 2015 | 47 | 0.480 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2017 | 217 | 0.480 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 105 | 0.480 |
Why?
|
| Papillomavirus Infections | 2 | 2014 | 263 | 0.480 |
Why?
|
| Urologic Neoplasms | 1 | 2015 | 88 | 0.480 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2016 | 154 | 0.480 |
Why?
|
| Overweight | 1 | 2015 | 119 | 0.470 |
Why?
|
| Television | 1 | 2014 | 29 | 0.460 |
Why?
|
| Famous Persons | 1 | 2014 | 8 | 0.460 |
Why?
|
| Papillomavirus Vaccines | 1 | 2014 | 58 | 0.460 |
Why?
|
| Acute Disease | 4 | 2021 | 842 | 0.450 |
Why?
|
| Health Behavior | 1 | 2015 | 186 | 0.450 |
Why?
|
| Stroke | 4 | 2021 | 988 | 0.450 |
Why?
|
| Vaccination | 2 | 2014 | 276 | 0.450 |
Why?
|
| Opioid-Related Disorders | 1 | 2016 | 192 | 0.430 |
Why?
|
| Empirical Research | 1 | 2013 | 19 | 0.430 |
Why?
|
| Epidemiologic Research Design | 1 | 2013 | 22 | 0.430 |
Why?
|
| Authorship | 1 | 2013 | 23 | 0.420 |
Why?
|
| Faculty, Medical | 1 | 2015 | 188 | 0.420 |
Why?
|
| Administration, Oral | 3 | 2020 | 682 | 0.420 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2024 | 77 | 0.410 |
Why?
|
| Crohn Disease | 1 | 2019 | 763 | 0.410 |
Why?
|
| Diet | 1 | 2015 | 443 | 0.400 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2022 | 1180 | 0.400 |
Why?
|
| Exercise | 1 | 2015 | 325 | 0.400 |
Why?
|
| Attitude | 1 | 2013 | 130 | 0.400 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 479 | 0.400 |
Why?
|
| Hypertension | 1 | 2017 | 747 | 0.390 |
Why?
|
| Biomedical Technology | 1 | 2011 | 21 | 0.390 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 298 | 0.380 |
Why?
|
| Surgical Wound Infection | 2 | 2024 | 201 | 0.380 |
Why?
|
| Myocardial Revascularization | 1 | 2011 | 30 | 0.380 |
Why?
|
| Electrocardiography | 4 | 2022 | 497 | 0.380 |
Why?
|
| Coronary Stenosis | 1 | 2011 | 39 | 0.370 |
Why?
|
| Primary Health Care | 1 | 2014 | 352 | 0.360 |
Why?
|
| Female | 17 | 2022 | 46439 | 0.350 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 983 | 0.340 |
Why?
|
| Clinical Trials as Topic | 2 | 2012 | 1152 | 0.340 |
Why?
|
| Neoplasms | 2 | 2021 | 3082 | 0.320 |
Why?
|
| Diagnosis, Differential | 4 | 2022 | 1601 | 0.320 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2021 | 699 | 0.300 |
Why?
|
| Warfarin | 2 | 2019 | 104 | 0.300 |
Why?
|
| Standard of Care | 3 | 2013 | 65 | 0.300 |
Why?
|
| Male | 14 | 2021 | 42632 | 0.290 |
Why?
|
| Adaptation, Psychological | 2 | 2019 | 166 | 0.290 |
Why?
|
| Heart Failure | 3 | 2022 | 1188 | 0.290 |
Why?
|
| Curriculum | 1 | 2012 | 568 | 0.290 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 2665 | 0.280 |
Why?
|
| Registries | 1 | 2011 | 792 | 0.280 |
Why?
|
| Acne Vulgaris | 2 | 2017 | 35 | 0.270 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 262 | 0.270 |
Why?
|
| Postoperative Complications | 2 | 2021 | 2290 | 0.260 |
Why?
|
| Middle Aged | 8 | 2021 | 26129 | 0.250 |
Why?
|
| Periodicals as Topic | 2 | 2019 | 168 | 0.230 |
Why?
|
| Advisory Committees | 2 | 2015 | 90 | 0.230 |
Why?
|
| Antimicrobial Stewardship | 1 | 2024 | 23 | 0.230 |
Why?
|
| Aged | 7 | 2022 | 19280 | 0.230 |
Why?
|
| United States Food and Drug Administration | 1 | 2024 | 136 | 0.230 |
Why?
|
| Quality Improvement | 2 | 2020 | 455 | 0.230 |
Why?
|
| Risk Factors | 3 | 2022 | 5522 | 0.220 |
Why?
|
| Faculty | 1 | 2023 | 33 | 0.220 |
Why?
|
| Professionalism | 1 | 2023 | 25 | 0.210 |
Why?
|
| Treatment Outcome | 4 | 2021 | 8283 | 0.210 |
Why?
|
| Leukocyte L1 Antigen Complex | 2 | 2020 | 47 | 0.210 |
Why?
|
| Weight Reduction Programs | 1 | 2022 | 13 | 0.210 |
Why?
|
| Tick Bites | 1 | 2022 | 1 | 0.200 |
Why?
|
| Child | 4 | 2022 | 7209 | 0.200 |
Why?
|
| Asymptomatic Diseases | 1 | 2022 | 45 | 0.200 |
Why?
|
| Frail Elderly | 1 | 2022 | 82 | 0.200 |
Why?
|
| Spiders | 1 | 2021 | 16 | 0.200 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 2370 | 0.190 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2021 | 60 | 0.190 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2022 | 55 | 0.190 |
Why?
|
| Necrosis | 1 | 2021 | 210 | 0.190 |
Why?
|
| Weight Loss | 2 | 2022 | 229 | 0.190 |
Why?
|
| Immunologic Factors | 2 | 2020 | 172 | 0.190 |
Why?
|
| Career Choice | 2 | 2021 | 148 | 0.190 |
Why?
|
| Internal Medicine | 3 | 2015 | 357 | 0.190 |
Why?
|
| Empathy | 1 | 2023 | 151 | 0.180 |
Why?
|
| Feces | 2 | 2020 | 331 | 0.180 |
Why?
|
| Foramen Ovale, Patent | 1 | 2021 | 18 | 0.180 |
Why?
|
| Acute Coronary Syndrome | 1 | 2021 | 30 | 0.180 |
Why?
|
| Embolectomy | 1 | 2020 | 6 | 0.180 |
Why?
|
| Drug Therapy, Combination | 2 | 2021 | 787 | 0.180 |
Why?
|
| Home Care Services | 1 | 2021 | 73 | 0.180 |
Why?
|
| History, 21st Century | 1 | 2021 | 182 | 0.180 |
Why?
|
| Recurrence | 2 | 2020 | 1144 | 0.170 |
Why?
|
| Cause of Death | 1 | 2021 | 270 | 0.170 |
Why?
|
| History, 20th Century | 1 | 2021 | 312 | 0.170 |
Why?
|
| Pulmonary Medicine | 1 | 2020 | 46 | 0.170 |
Why?
|
| Time Factors | 2 | 2019 | 5346 | 0.170 |
Why?
|
| Europe | 1 | 2020 | 322 | 0.170 |
Why?
|
| Anxiety | 1 | 2022 | 311 | 0.170 |
Why?
|
| Colonic Polyps | 1 | 2020 | 132 | 0.170 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2021 | 145 | 0.170 |
Why?
|
| Irritable Bowel Syndrome | 2 | 2020 | 46 | 0.170 |
Why?
|
| Schools, Medical | 1 | 2020 | 134 | 0.170 |
Why?
|
| Communication | 1 | 2023 | 460 | 0.170 |
Why?
|
| Hepatitis C | 1 | 2021 | 174 | 0.160 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 1721 | 0.160 |
Why?
|
| Salvage Therapy | 1 | 2020 | 236 | 0.160 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2019 | 52 | 0.160 |
Why?
|
| Mitral Valve | 1 | 2021 | 262 | 0.160 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2021 | 192 | 0.160 |
Why?
|
| Illinois | 1 | 2020 | 483 | 0.160 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 31 | 0.160 |
Why?
|
| Endovascular Procedures | 1 | 2023 | 286 | 0.160 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2018 | 8 | 0.160 |
Why?
|
| Pandemics | 1 | 2024 | 776 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 203 | 0.160 |
Why?
|
| Thyroid Diseases | 1 | 2019 | 105 | 0.160 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2019 | 53 | 0.160 |
Why?
|
| Adenoma | 1 | 2020 | 247 | 0.160 |
Why?
|
| Remission Induction | 2 | 2020 | 741 | 0.150 |
Why?
|
| Influenza, Human | 2 | 2000 | 339 | 0.150 |
Why?
|
| Egg Hypersensitivity | 1 | 2018 | 4 | 0.150 |
Why?
|
| Blood Coagulation Tests | 1 | 2018 | 35 | 0.150 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 57 | 0.150 |
Why?
|
| Eczema | 1 | 2018 | 7 | 0.150 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 111 | 0.150 |
Why?
|
| Vancomycin | 1 | 2018 | 73 | 0.150 |
Why?
|
| Syncope | 1 | 2018 | 34 | 0.150 |
Why?
|
| Education, Medical, Continuing | 1 | 2019 | 105 | 0.150 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2018 | 64 | 0.150 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2018 | 33 | 0.150 |
Why?
|
| Proton Pump Inhibitors | 1 | 2018 | 34 | 0.150 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2021 | 261 | 0.150 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2019 | 200 | 0.150 |
Why?
|
| Endoscopy | 1 | 2021 | 351 | 0.150 |
Why?
|
| Defibrillators, Implantable | 1 | 2019 | 145 | 0.150 |
Why?
|
| Rivaroxaban | 1 | 2017 | 12 | 0.150 |
Why?
|
| Research Report | 2 | 2019 | 44 | 0.140 |
Why?
|
| Review Literature as Topic | 1 | 2017 | 21 | 0.140 |
Why?
|
| Mentors | 1 | 2018 | 88 | 0.140 |
Why?
|
| Aortic Valve Stenosis | 1 | 2019 | 144 | 0.140 |
Why?
|
| Dabigatran | 1 | 2017 | 25 | 0.140 |
Why?
|
| Thyroxine | 1 | 2019 | 353 | 0.140 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 28 | 0.140 |
Why?
|
| Intestinal Obstruction | 1 | 2017 | 89 | 0.140 |
Why?
|
| Continuity of Patient Care | 1 | 2019 | 172 | 0.140 |
Why?
|
| Aortic Valve | 1 | 2019 | 244 | 0.140 |
Why?
|
| Meta-Analysis as Topic | 1 | 2017 | 81 | 0.140 |
Why?
|
| Pyridones | 1 | 2017 | 56 | 0.140 |
Why?
|
| Physical Therapy Modalities | 1 | 2017 | 83 | 0.140 |
Why?
|
| Bone Density | 1 | 2018 | 209 | 0.140 |
Why?
|
| Personal Satisfaction | 1 | 2017 | 63 | 0.140 |
Why?
|
| Coronary Angiography | 2 | 2021 | 242 | 0.140 |
Why?
|
| Thiazoles | 1 | 2017 | 128 | 0.140 |
Why?
|
| Analgesics | 1 | 2017 | 119 | 0.140 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2017 | 104 | 0.130 |
Why?
|
| Device Approval | 2 | 2013 | 13 | 0.130 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 147 | 0.130 |
Why?
|
| Pyrazoles | 1 | 2017 | 150 | 0.130 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 345 | 0.130 |
Why?
|
| Erythrocyte Transfusion | 1 | 2016 | 72 | 0.130 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 48 | 0.130 |
Why?
|
| Contraindications | 2 | 2015 | 70 | 0.130 |
Why?
|
| Tinnitus | 1 | 2016 | 21 | 0.130 |
Why?
|
| Biomarkers | 2 | 2020 | 1771 | 0.130 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 144 | 0.130 |
Why?
|
| Disease Progression | 1 | 2020 | 1493 | 0.130 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2016 | 110 | 0.130 |
Why?
|
| Obesity | 1 | 2022 | 972 | 0.130 |
Why?
|
| Physician's Role | 1 | 2017 | 177 | 0.130 |
Why?
|
| Unnecessary Procedures | 1 | 2015 | 52 | 0.130 |
Why?
|
| Pregnancy | 3 | 2022 | 3030 | 0.130 |
Why?
|
| Immunotherapy | 1 | 2021 | 693 | 0.120 |
Why?
|
| Immunization, Secondary | 1 | 2015 | 33 | 0.120 |
Why?
|
| Pyridines | 1 | 2017 | 316 | 0.120 |
Why?
|
| Asthma | 2 | 2022 | 980 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1721 | 0.120 |
Why?
|
| Learning | 1 | 2018 | 285 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 972 | 0.120 |
Why?
|
| Vaginal Smears | 1 | 2014 | 71 | 0.120 |
Why?
|
| Life Expectancy | 1 | 2014 | 89 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2019 | 436 | 0.120 |
Why?
|
| Laparoscopy | 1 | 2021 | 775 | 0.120 |
Why?
|
| Gastrointestinal Agents | 1 | 2015 | 172 | 0.110 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2015 | 95 | 0.110 |
Why?
|
| Retrospective Studies | 2 | 2024 | 9100 | 0.110 |
Why?
|
| Blood Pressure | 1 | 2017 | 903 | 0.110 |
Why?
|
| Colitis, Ulcerative | 1 | 2020 | 748 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2017 | 950 | 0.110 |
Why?
|
| Journal Impact Factor | 1 | 2013 | 15 | 0.110 |
Why?
|
| Peer Review, Research | 1 | 2013 | 36 | 0.110 |
Why?
|
| Pharmacogenetics | 1 | 2017 | 443 | 0.110 |
Why?
|
| Comorbidity | 1 | 2017 | 951 | 0.110 |
Why?
|
| Observation | 1 | 2013 | 38 | 0.110 |
Why?
|
| Prostate-Specific Antigen | 1 | 2015 | 360 | 0.110 |
Why?
|
| Patient Care | 1 | 2014 | 102 | 0.110 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 460 | 0.110 |
Why?
|
| Sex Factors | 1 | 2016 | 1070 | 0.100 |
Why?
|
| Clinical Competence | 2 | 2015 | 785 | 0.100 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 2025 | 0.100 |
Why?
|
| Problem-Based Learning | 1 | 2012 | 35 | 0.100 |
Why?
|
| Gramicidin | 1 | 1992 | 24 | 0.100 |
Why?
|
| Phosphatidylcholines | 1 | 1992 | 49 | 0.100 |
Why?
|
| Conflict of Interest | 1 | 2011 | 69 | 0.100 |
Why?
|
| Infant | 1 | 2018 | 3171 | 0.090 |
Why?
|
| Lipid Bilayers | 1 | 1992 | 137 | 0.090 |
Why?
|
| Smoking | 1 | 2014 | 624 | 0.090 |
Why?
|
| Pulmonary Artery | 1 | 2012 | 319 | 0.090 |
Why?
|
| Ion Channels | 1 | 1992 | 246 | 0.090 |
Why?
|
| Fibrinolytic Agents | 2 | 2022 | 217 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 3672 | 0.080 |
Why?
|
| Incidence | 1 | 2012 | 1599 | 0.080 |
Why?
|
| Stroke Volume | 2 | 2021 | 465 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 6847 | 0.070 |
Why?
|
| HIV Infections | 1 | 2016 | 846 | 0.070 |
Why?
|
| Young Adult | 2 | 2017 | 6360 | 0.070 |
Why?
|
| Models, Biological | 1 | 1992 | 1767 | 0.060 |
Why?
|
| Drug Resistance, Microbial | 1 | 2024 | 75 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 1793 | 0.060 |
Why?
|
| Doxycycline | 1 | 2022 | 28 | 0.050 |
Why?
|
| Animals | 1 | 2021 | 27456 | 0.050 |
Why?
|
| Contraindications, Procedure | 1 | 2021 | 7 | 0.050 |
Why?
|
| Contraindications, Drug | 1 | 2021 | 4 | 0.050 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2023 | 89 | 0.050 |
Why?
|
| Nephrologists | 1 | 2021 | 10 | 0.050 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2021 | 4 | 0.050 |
Why?
|
| Urinalysis | 1 | 2021 | 31 | 0.050 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2021 | 6 | 0.050 |
Why?
|
| Blood Loss, Surgical | 1 | 2022 | 115 | 0.050 |
Why?
|
| Troponin | 1 | 2021 | 24 | 0.050 |
Why?
|
| Septal Occluder Device | 1 | 2021 | 45 | 0.050 |
Why?
|
| Age Factors | 2 | 2015 | 1876 | 0.050 |
Why?
|
| Hepacivirus | 1 | 2021 | 131 | 0.040 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2021 | 64 | 0.040 |
Why?
|
| Device Removal | 1 | 2021 | 168 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2000 | 156 | 0.040 |
Why?
|
| Aftercare | 1 | 2020 | 87 | 0.040 |
Why?
|
| Influenza Vaccines | 1 | 2000 | 150 | 0.040 |
Why?
|
| Ischemic Attack, Transient | 1 | 2021 | 182 | 0.040 |
Why?
|
| Global Health | 1 | 2000 | 192 | 0.040 |
Why?
|
| Aminoglycosides | 1 | 2018 | 32 | 0.040 |
Why?
|
| Heart Valve Prosthesis | 1 | 2019 | 98 | 0.040 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2018 | 40 | 0.040 |
Why?
|
| Wounds and Injuries | 1 | 2021 | 260 | 0.040 |
Why?
|
| Postpartum Period | 1 | 2019 | 144 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2018 | 82 | 0.040 |
Why?
|
| Thyrotropin | 1 | 2019 | 289 | 0.040 |
Why?
|
| Reference Values | 1 | 2019 | 663 | 0.040 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2017 | 12 | 0.040 |
Why?
|
| Forecasting | 1 | 2019 | 306 | 0.040 |
Why?
|
| Spirometry | 1 | 2017 | 66 | 0.040 |
Why?
|
| Drug Labeling | 1 | 2017 | 41 | 0.040 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2019 | 178 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2000 | 480 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2016 | 73 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2018 | 298 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2015 | 223 | 0.030 |
Why?
|
| Disease Management | 1 | 2017 | 329 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2015 | 277 | 0.030 |
Why?
|
| Gastroenterology | 1 | 2015 | 146 | 0.030 |
Why?
|
| Models, Structural | 1 | 1992 | 58 | 0.030 |
Why?
|
| Vertebroplasty | 1 | 2012 | 8 | 0.020 |
Why?
|
| Spinal Injuries | 1 | 2012 | 23 | 0.020 |
Why?
|
| Mathematics | 1 | 1992 | 191 | 0.020 |
Why?
|
| Prostate | 1 | 2015 | 403 | 0.020 |
Why?
|
| Macromolecular Substances | 1 | 1992 | 177 | 0.020 |
Why?
|
| Biopsy | 1 | 2015 | 1185 | 0.020 |
Why?
|
| Drug Approval | 1 | 2012 | 66 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 2882 | 0.020 |
Why?
|
| Testosterone | 1 | 2012 | 276 | 0.020 |
Why?
|
| Adolescent | 1 | 2022 | 9295 | 0.020 |
Why?
|
| Kinetics | 1 | 1992 | 1534 | 0.020 |
Why?
|
| Stents | 1 | 2012 | 409 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 4328 | 0.020 |
Why?
|
| Writing | 1 | 2008 | 29 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2012 | 364 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 2643 | 0.020 |
Why?
|
| Thromboembolism | 1 | 2000 | 120 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2000 | 151 | 0.010 |
Why?
|